Health and Medicine

FSI’s researchers assess health and medicine through the lenses of economics, nutrition and politics. They’re studying and influencing public health policies of local and national governments and the roles that corporations and nongovernmental organizations play in providing health care around the world. Scholars look at how governance affects citizens’ health, how children’s health care access affects the aging process and how to improve children’s health in Guatemala and rural China. They want to know what it will take for people to cook more safely and breathe more easily in developing countries.

FSI professors investigate how lifestyles affect health. What good does gardening do for older Americans? What are the benefits of eating organic food or growing genetically modified rice in China? They study cost-effectiveness by examining programs like those aimed at preventing the spread of tuberculosis in Russian prisons. Policies that impact obesity and undernutrition are examined; as are the public health implications of limiting salt in processed foods and the role of smoking among men who work in Chinese factories. FSI health research looks at sweeping domestic policies like the Affordable Care Act and the role of foreign aid in affecting the price of HIV drugs in Africa.

News Type
News
Date
Paragraphs

Paul Farmer, MD, PhD, a physician, infectious disease expert and medical anthropologist who has dedicated his life to treating some of the world's poorest populations, spoke to an overflow crowd on April 8, 2004 at the Stanford Institute for International Studies. Farmer spoke in his capacity as the inaugural S.T. Lee Lecturer.

In his talk, titled "The Nexus of Health and Human Rights," Farmer spoke about the clinic he directs in Cange, Haiti. The clinic has become the center of a thriving community-based medical care system that is tackling Haiti's HIV problem head-on, demonstrating that complex medical treatments can be implemented successfully in poor, underdeveloped nations. Farmer, who has won several awards for his humanitarian work, also talked about promoting access to medical care as a basic human right.

The S.T. Lee Lectureship is named for Seng Tee Lee, a business executive and noted philanthropist. Mr. Lee endowed the lectureship in order to raise public understanding of the complex policy issues facing the global community today.

All News button
1
Authors
Donald Kennedy
News Type
Commentary
Date
Paragraphs

The national debate over human embryonic stem cell research -- one that has pitted religious objections against the promise of major scientific and therapeutic advances -- has been reawakened by a dramatic advance that could have been made in the United States, but wasn't. That's because on Aug. 9, 2001, President Bush announced that only stem cell lines obtained before that date could be used in research supported by federal funds. This has virtually halted a vital area of medical science here because development of an equivalent level of private support will require many years. And that's why the new excitement comes from South Korea, not from this country. The stakes are high. Stem cells, which can be obtained from human embryos otherwise discarded at fertility clinics in the course of assisted reproduction, are capable of forming all of the tissues of the adult human body under the right circumstances. They are of enormous potential advantage in the treatment of Parkinson's disease, spinal cord injuries, Alzheimer's disease and diabetes. So what's wrong with the dozen or so old cell lines we have? The problem is that most of the approved lines are unavailable, or otherwise guarded by murky intellectual property claims. The way they were made and their limited genetic diversity limit their therapeutic utility. More important, new technology has taken us beyond their capacity. The recent experiments performed in South Korea have produced a robust line of stem cells, derived from blastocysts that were produced by activating eggs taken from female volunteers with nuclei taken from body cells of the donor. This process, called somatic cell nuclear transfer, is viewed by some as akin to cloning people, which no one in the scientific community favors. Instead, it provides a way to explore the early processes of human development and develop novel ways of understanding the basis for genetic predisposition to late-onset diseases. It is essential research, and it is needed here. Yet if the congressional opponents of stem cell research have their way, a bill already passed by the House and now being considered in the Senate would make such work a crime. In South Korea, cloning for reproductive purposes is against the law. But this work, plainly aimed at scientific and therapeutic purposes, was encouraged and supported by the government. If we decide to discourage or even criminalize such experiments here, they will be done elsewhere -- and the benefits will be reaped by others. One option in this country is to approach a solution at the state level. Some states have passed laws that make cloning people illegal but allow cloning stem cells -- an important distinction that Congress has so far been unwilling to make. And some states have developed the means for raising funds to support the kind of research that now cannot be done with federal funds. A forthcoming ballot initiative in California would appropriate $350 million each year to support stem cell research. It would create a California Stem Cell Research and Cures Fund, to be distributed by an Institute for Regenerative Medicine, overseen by an independent citizens committee selected from academic and research institutions. The funding plan rests on the authorization of a $3 billion general obligation bond issue. For the first five years, a positive tax revenue stream generated by the initial expenditures will make it possible not to burden the state's general fund while it recovers from its present economic stress. The California experiment is an interesting one. As Californians and scientists, we hope for its success. But we also hope that it will be a signal for other citizens -- that there are domestic alternatives to a national policy that threatens to drive an important and valuable research activity overseas. A California resolution would be nice for us, and for the California economy. But if we can't find a solution that permits stem cell research at the federal level, the result will be costly for our national health.

  • DAVID BALTIMORE is president of the California Institute of Technology;
  • PAUL BERG is a professor of biochemistry at Stanford University;
  • DONALD KENNEDY, former Stanford president, is editor-in-chief of Science magazine; and
  • IRV WEISSMAN is a professor of cancer biology at Stanford. They wrote this column for the Mercury News.
All News button
1
-

Medical anthropologist and physician Paul Farmer has dedicated his life to treating some of the world's poorest populations, in the process helping to raise the standard of health care in underdeveloped areas of the world. Paul Farmer has worked in infectious-disease control in the Americas for nearly two decades and is a world-renowned authority on tuberculosis treatment and control. Dr. Farmer has pioneered novel, community-based treatment strategies for infectious diseases (including HIV/AIDS and multidrug-resistant tuberculosis) in resource-poor settings.

In 1993, he was awarded a John D. and Catherine T. MacArthur Foundation Genius Award in recognition of his work, and in 2003 the Heinz Award for the Human Condition.

Bechtel Conference Center

Dr. Paul Farmer Professor of Medicine and Medical Anthropology, Harvard University and Medical Director, Clinique Bon Sauveur, Cange, Haiti
Lectures
-

Drell Lecture Recording: NA

 

Drell Lecture Transcript: 

 

Speaker's Biography: Richard Garwin is IBM Fellow Emeritus at the Thomas J. Watson Research Center, Yorktown Heights, New York. After three years on the faculty of the University of Chicago, he joined IBM Corporation in 1952, and was until June 1993 IBM Fellow at the Thomas J. Watson Research Center, Yorktown Heights, New York; Adjunct Research Fellow in the Kennedy School of Government, Harvard University; and Adjunct Professor of Physics at Columbia University. In addition, he is a consultant to the U.S. government on matters of military technology, arms control, etc. He has been Director of the IBM Watson Laboratory, Director of Applied Research at the IBM Thomas J. Watson Research Center, and a member of the IBM Corporate Technical Committee. He has also been Professor of Public Policy in the Kennedy School of Government, Harvard University. From 1994 to 2004 he was Philip D. Reed Senior Fellow for Science and Technology at the Council on Foreign Relations, New York.

He has made contributions in the design of nuclear weapons, in instruments and electronics for research in nuclear and low-temperature physics, in the establishment of the nonconservation of parity and the demonstration of some of its striking consequences, in computer elements and systems, including superconducting devices, in communication systems, in the behavior of solid helium, in the detection of gravitational radiation, and in military technology. He has published more than 500 papers and been granted 45 U.S. patents. He has testified to many Congressional committees on matters involving national security, transportation, energy policy and technology, and the like. He is coauthor of many books, among them Nuclear Weapons and World Politics (1977), Nuclear Power Issues and Choices (1977), Energy: The Next Twenty Years (1979), Science Advice to the President (1980), Managing the Plutonium Surplus: Applications and Technical Options (1994), Feux Follets et Champignons Nucleaires (1997) (in French with Georges Charpak), and Megawatts and Megatons: A Turning Point in the Nuclear Age? (2001) (with Georges Charpak).

He was a member of the President's Science Advisory Committee 1962-65 and 1969-72, and of the Defense Science Board 1966-69. He is a Fellow of the American Physical Society, of the IEEE, and of the American Academy of Arts and Sciences; and a member of the National Academy of Sciences, the Institute of Medicine, the National Academy of Engineering, the Council on Foreign Relations, and the American Philosophical Society. In 2002 he was elected again to the Council of the National Academy of Sciences.

His work for the government has included studies on antisubmarine warfare, new technologies in health care, sensor systems, military and civil aircraft, and satellite and strategic systems, from the point of view of improving such systems as well as assessing existing capabilities. For example, he contributed to the first U.S. photographic reconnaissance satellite program, CORONA, that returned 3 million feet of film from almost 100 successful flights 1960-1972.

He has been a member of the Scientific Advisory Group to the Joint Strategic Target Planning Staff and was in 1998 a Commissioner on the 9-person "Rumsfeld" Commission to Assess the Ballistic Missile Threat to the United States. From 1993 to August 2001, he chaired the Arms Control and Nonproliferation Advisory Board of the Department of State. On the 40th anniversary of the founding of the National Reconnaissance Office (NRO) he was recognized as one of the ten Founders of National Reconnaissance. In June, 2002, he was awarded la Grande Medaille de l'Academie des Sciences (France)-2002.

Cubberly Auditorium, Stanford University

Dr. Richard L. Garwin Senior Fellow Science and Technology Council on Foreign Relations, NY
Lectures
-

This seminar is part of SPRIE's Fall 2003 series on "High-Tech Regions and the Globalization of Value Chains."

Eric Benhamou is the chairman of the board of directors of 3Com Corporation, of Palm Inc. and of PalmSource, Inc. He served as chief executive officer of 3Com Corporation from September 1990 until December 31, 2000. In 1981, Benhamou co-founded Bridge Communications, an early networking pioneer, and was vice president of engineering until its merger with 3Com in 1987. Before joining Bridge Communications, he worked at Zilog, Inc. as project manager, software engineering manager and design engineer.

Benhamou holds honorary doctoral degrees from Ben Gurion University of the Negev, Widener University, Western Governors University, and the University of South Carolina. He has a master of science degree in electrical engineering from Stanford University and a Diplome d'Ingenieur from Ecole Nationale Superieure d'Arts et Metiers, Paris.

Benhamou currently serves as chairman of the board of Cypress Semiconductor and as a member of the board of Legato. He serves on the board of directors of privately held companies, Intransa and Atrica. He serves on the board of the New America Foundation, a Washington DC-based think tank. Benhamou serves on the executive committee of TechNet and of the Computer Science and Technology Board (CSTB). In addition, Benhamou is a champion of Smart Valley II, an initiative for deployment of state-of-the art information technology in Silicon Valleys health care, transportation, and education to enhance the quality of life for community members.

Philippines Conference Room

Eric Benhamou Chairman, Board of Directors 3Com Corporation, Palm, Inc., and PalmSource, Inc.
Seminars

Shorenstein APARC's Korean Studies Program, begun in September 2000 and led by Gi-Wook Shin, features weekly luncheon seminars on Korea-related issues, from war reporting to health care to democracy. Heavily attended by students and faculty alike, the series is often standing-room-only.

Graduate School of Business
Stanford University
Stanford, CA 94305-5015

(650) 723-2160 (650) 725-7979
0
Richard A. Stepp Professor of Economics
bulow.jpg MA, PhD
Stanford Health Policy Associate

Project Goal
To create and apply a methodology for the review of quality improvement implementation strategies -- approaches to closing the "quality gap" between ideal and actual care -- in national priority areas identified recently by the Institute of Medicine (IOM). These priority areas were selected by the IOM based on the notion that most quality problems in health care arise not from a lack of effective clinical practices, but rather from inadequate delivery strategies for implementing these practices.

-

This is a presentation of joint work with Dr. Rafiq Dossani, Shorenstein APARC. About the Talk: IT (Information Technology) outsourcing has become a standard approach for many Fortune 3000 and smaller companies to achieve cost-effectiveness. However, while outsourcing at the low end of the value chain has gained acceptance, many issues remain unresolved at the high end of the IT value chain. We develop a characterization of outsourcing firms, suppliers, and tasks that is useful in providing guidelines on when to outsource, and whom to outsource to. These guidelines for IT outsourcing strategies are based on a study of US customers, and Indian IT suppliers, involving questionnaires and interviews. To our knowledge, this is first study that has captured the supplier characteristics in the level of detail, which will be discussed by Dr. Akella in his talk. Professor Ram Akella is currently professor of IE and Management, and was the founding director, SUNY Center for Excellence in Global Enterprise Management. At Stanford, the University of California, Berkeley, and Carnegie Mellon University, as a faculty member and director, Professor Akella has led major multi-million dollar interdisciplinary team efforts in high tech and semiconductors. His current research interests include in process learning, quality, fab economic models, cost of ownership and financial justification for IT Management and equipment, production planning and control, and bio-informatics. His other interests are enterprise systems, IT and software, financial engineering, high tech and e-business, and range from cell and factory level design and control to enterprise-wide coordination and logistics, including supply chain management and contracts, financial engineering and investment, demand management, e-commerce and e-business exchanges, and product and process portfolios for risk management and design capacity management.

Daniel and Nancy Okimoto Conference Room

Ram Akella Professor, IE and Management SUNY
Seminars
-

Dr. Myron Cohen spoke earlier this year at the UN on AIDS in China. He has been very active in organizing medical research on AIDS in China and only recently returned from a conference held there in November on the subject.

Philippines Conference Room, Third Floor, Cemtral Wing, Encina Hall

Seminars
Subscribe to Health and Medicine